Increased Brain GABA Concentrations Following Acute Administration of a Selective Serotonin Reuptake Inhibitor

We recruited 10 healthy volunteers (nine men and one woman; mean age=41.6 years, range=20–67) who had no history of any DSM-IV axis I disorder according to the Structured Clinical Interview for DSM-IV. None acknowledged a history of depression in a first-degree relative. All subjects had been free of psychotropic medication for at least 3 months and gave written informed consent for the study, which was approved by the local ethics committee.

Subjects were scanned (eyes open) on two occasions (mean test interval=12.2 days, range=4–37) after receiving either intravenous citalopram (10 mg) or saline over 30 minutes in a randomized, double-blind, crossover design. MRS spectra were acquired from subjects between 40 and 65 minutes after completion of the infusion. The 10-mg dose of citalopram was chosen on the basis of a previous dose-response study that showed reliable 5-HT neuroendocrine responses in the absence of significant subjective side effects (5).

To measure occipital total GABA (GABA and the GABA dipeptide homocarnosine), we applied a proton MR spectral editing technique based on a spatially localized (point-resolved spectroscopy [6]) double-quantum filter (7). This single-shot technique (256 averages, TR=3 seconds) allowed us to detect the GABA-CH₂ resonance (3 ppm) with suppression of uncoupled resonances from choline, creatine, and N-acetylaspartate. The localized double-quantum filter method was implemented on a 3-T Varian-Inova spectrometer with a standard birdcage head coil; 27 cm³ (3×3×3 cm³) voxels were placed in the occipital lobe region guided by T₁-weighted axial images. We studied the occipital lobe because it offers clear landmarks for consistent placement of the spectroscopic voxel and is removed from major sources of static magnetic field inhomogeneities in the head, allowing narrower spectroscopic line widths to be achieved. We also acquired a standard point-resolved spectroscopy spectrum (TE=68 msec, TR=3 seconds) in order to measure signal intensities from choline, creatine, and N-acetylaspartate. Three-dimensional structural images (T₁-weighted, gradient echo imaging providing 32 32-mm slices) were used for voxel segmentation to estimate gray matter content in the MRS voxel.

Spectra were analyzed by using Magnetic Resonance User Interface software (MRUI project: http://carbon.uab.es/mrui/) with frequency-selective, time domain-fitting VARPRO (8). We calculated GABA/creatine ratios after correcting for editing efficiency and number of equivalent protons in GABA and creatine; we assumed that the saturations of GABA and creatine resonances were similar. These GABA/creatine ratios can be converted to absolute concentrations of GABA, given known concentrations of creatine in the brain (assumed to be 7 mM, based on measured, approximately equal voxel concentrations of gray and white matter). Differences in GABA levels after pretreatment with saline and citalopram were compared by using a paired t test, and Pearson’s product-moment correlation analyses were performed. Scan/rescan reliability, calculated as twice the standard deviation of the difference in measurements on two occasions without drug administration, was 26.7%.

There was a mean rise of 34.5% (SE=13.5) in the GABA/creatine ratio after the citalopram infusion (mean=0.36, SE=0.10) compared with saline (mean=0.28, SE=0.005) (t=2.51, df=9, p<0.04) (Figure 1). Estimated mean GABA concentrations were 1.96 mmol/kg (SE=0.35) after placebo and 2.52 mmol/kg (SE=0.70) after citalopram. There was no correlation between the change in GABA/creatine ratio following citalopram and age, the interval between the start of the infusion and acquisition of the spectrum, number of days between the scans, or body weight (all p values >0.10). Visual analogue scales measuring anxiety and somatic symptoms did not distinguish citalopram from placebo administration.

Our data indicate that acute intravenous administration of the SSRI citalopram increases total occipital GABA levels in healthy volunteers. The magnitude of this increase was very similar to that reported by Sanacora and colleagues (3), who studied depressed patients before and after an average of 8 weeks of SSRI treatment. Our findings therefore suggest that SSRI treatment can increase occipital GABA levels independent of clinical changes in mood. Although three subjects did not show an increase in occipital GABA levels after citalopram, most biological responses to 5-HT challenge show substantial interindividual variation. In a previous study (3), two of 11 depressed patients did not show an increase in brain GABA after chronic SSRI treatment. Genetic polymorphisms in 5-HT receptors may determine some of these individual differences (9).

The increase in occipital GABA levels after acute citalopram administration could reflect interactions of 5-HT pathways with GABAergic neurons. The ascending 5-HT innervation of the cortex preferentially targets GABA interneurons, and consistent with this, electrophysiological studies have shown increased activity of GABA interneurons following administration of 5-HT_2A and 5-HT₃ receptor agonists (10). It must be acknowledged, however, that there are many other less specific ways in which citalopram might alter brain GABA levels, including effects on the function of synthetic enzymes, glucose metabolism, or glutamate/glutamine cycling.

Networks of GABA interneurons can synchronize activity within local populations of pyramidal neurons and perhaps also across distributed neural networks (11). It has been proposed that disruption of this synchrony may underlie various kinds of neurological and psychological dysfunction (12), so modulatory effects of SSRIs on cortical GABA may provide new insights into therapeutic mechanisms.

Received Jan. 24, 2003; revision received July 9, 2003; accepted July 15, 2003. From the University Department of Psychiatry, Warneford Hospital; and the Centre for Functional Magnetic Imaging of the Brain, Department of Clinical Neurology, John Radcliffe Hospital, Oxford, U.K. Address reprint requests to Dr. Cowen, University Department of Psychiatry, Warneford Hospital, Oxford, OX3 7JX, U.K.; [email protected]. Supported by the Medical Research Council (U.K.).